IL3RA and acute myeloid leukemia: An example of these antibodies is represented by the neutralizing anti-CD123 7G3 monoclonal antibody, first humanized and affinity matured, and then engineered at the level of the Fc-domain to potentiate its cytotoxicity-inducing capacity against AML cells; the antibody thus modified was called CSL362 and was explored first in preclinical studies and then in clinical trials in AML patients [64].